(Total Views: 694)
Posted On: 11/02/2022 6:33:26 AM
Post# of 153815
A basic fact I learned from the arbitration claim helpfully posted on Stockwits: Amarex was the CRO on 20 of the 22 trials CYDY has run. As of Oct. 2021, four of these were ongoing.
This claim was posted over a year ago, meaning the arbitration process must soon come to an end.
One more thing. I've mentioned this here before, but just to reinforce it: Amarex is clearly liable for lost revenues. I held a company involved in a suit that dated from 2006; there were NO revenues when the suit was filed in 2006, and there would be no revenues until 2010, but the judge held that the losing company was liable for revenues that were literally imaginary when the suit was filed. The plaintiff presented a case for revenues that might eventually ensue, and the judge essentially made his own estimate ($100 million in that case). So even though it's not exactly clear now HOW MUCH CYDY would have profited from a successful application for HIV MDR, such things can be estimated, and awarded.
The costs of the toxic financing that resulted from Amarex's mistakes or malfeasance are entirely clear, and they are huge.
To me the only question is whether Sidley Austin can prove that NSF should be on the hook, and for how much. If we can be privy to emails back and forth from NSF and Amarex, it should become clear. And, for NSF, probably pretty expensive.
This claim was posted over a year ago, meaning the arbitration process must soon come to an end.
One more thing. I've mentioned this here before, but just to reinforce it: Amarex is clearly liable for lost revenues. I held a company involved in a suit that dated from 2006; there were NO revenues when the suit was filed in 2006, and there would be no revenues until 2010, but the judge held that the losing company was liable for revenues that were literally imaginary when the suit was filed. The plaintiff presented a case for revenues that might eventually ensue, and the judge essentially made his own estimate ($100 million in that case). So even though it's not exactly clear now HOW MUCH CYDY would have profited from a successful application for HIV MDR, such things can be estimated, and awarded.
The costs of the toxic financing that resulted from Amarex's mistakes or malfeasance are entirely clear, and they are huge.
To me the only question is whether Sidley Austin can prove that NSF should be on the hook, and for how much. If we can be privy to emails back and forth from NSF and Amarex, it should become clear. And, for NSF, probably pretty expensive.
(19)
(0)
